01The molecule
Psilocybin becomes psilocin.
Your body converts psilocybin into psilocin. Psilocin and LSD do not simply add more serotonin; their shape lets them attach to some of the receptors normally used by serotonin.
Psilocybin + LSD research
Small doses. Meaningful shifts.
People are exploring microdosing to feel more connected, creative and emotionally well. Here are the positive stories showing up in the science.
Explore the researchThe practice
What people are exploring.
Microdosing psilocybin or LSD means working with an amount intended to sit below a full psychedelic experience, often as part of a repeating practice woven into everyday life.
The reasons are personal: a brighter mood, renewed curiosity, deeper connection, more creative energy or a different relationship with discomfort. Research is beginning to give those experiences shape.
Brain basics
Psychedelics and the brain, in plain English.
Think of it as keys, locks and ripple effects. LSD and psilocin—the active form your body makes from psilocybin—are shaped enough like serotonin to fit some of the same locks in the brain.
02The receptor
The main lock is called 5-HT2A.
A receptor is like a lock on a brain cell. Both substances produce much of their psychedelic effect by turning 5-HT2A locks, especially on cells in the cortex—the outer layer involved in perception and thought.
03The ripple
That changes the conversation.
Those cortical cells change how they fire and influence glutamate, the brain’s main ‘go’ messenger. At larger research doses, familiar brain networks become less synchronized, allowing information to combine in less usual ways.
04Plasticity
The brain may become more change-ready.
Animal studies show that psilocybin can grow and reshape tiny connection points between neurons. Scientists call this plasticity. It is a window for change—not proof that every change is beneficial.
Signals in the science
Positive outcomes worth following.
Psilocybin + mood
A month-long study found small-to-medium improvements in mood and mental health among psilocybin microdosers compared with non-microdosing participants, across age, gender and the presence of mental health concerns.
Psilocybin + the brain
In a double-blind human study, a psilocybin microdose produced a measurable reduction in theta-band EEG power. Preclinical research also found strengthened connections between the cortex and thalamus after repeated low doses.
Lived experience
People who microdose psilocybin or LSD most often report improved mood, focus and creativity. Controlled LSD research adds dose-day signals of connectedness, energy, happiness and wellness.
Reading the evidence
Hopeful and honest can coexist.
- 01
Observed improvement is a valuable signal. A randomized placebo-controlled result gives stronger evidence that the substance contributed to it.
- 02
A positive dose-day experience is different from a lasting therapeutic change. Both can be meaningful, but they answer different questions.
- 03
A measurable brain change is not automatically a therapeutic benefit. The human psilocybin EEG study found altered rhythms without improved cognition or wellbeing.
- 04
These studies investigated specific research samples and settings. They do not establish microdosing as a treatment for a medical condition.
Read the research
Follow the findings to their source.
Every central outcome on this page comes from a peer-reviewed paper focused specifically on LSD or psilocybin microdosing.
Psilocybin · observationalPsilocybin microdosers demonstrate greater observed improvements in mood and mental health at one monthScientific Reports, 2022Psilocybin · human neuroscienceMicrodosing with psilocybin mushrooms: a double-blind placebo-controlled EEG studyTranslational Psychiatry, 2022Psilocybin · PET receptor imagingPsychedelic effects correlate with serotonin 2A receptor occupancy and plasma psilocin levelsNeuropsychopharmacology, 2019Psilocybin · neurotransmitter imagingRegional alterations in glutamate and the experience of ego dissolution with psilocybinNeuropsychopharmacology, 2020Psilocybin · human brain networksPsilocybin desynchronizes the human brainNature, 2024Psilocybin · preclinical plasticityPsilocybin induces rapid and persistent growth of dendritic spines in frontal cortexNeuron, 2021Psilocybin · preclinical neuroscienceRepeated low doses increase stress resilience and strengthen cortical–thalamic connections in ratsMolecular Psychiatry, 2023Psilocybin + LSD · qualitative surveyPsychedelic microdosing benefits and challenges: an empirical codebookHarm Reduction Journal, 2019LSD · randomized controlledAcute mood-elevating properties of microdosed LSD in healthy volunteersBiological Psychiatry, 2023
One-to-one consultation
Curious about what this could mean for you?
A consultation is a place to explore your intentions, the emerging evidence and your wider health context with care and curiosity.